Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by LVW Advisors LLC

LVW Advisors LLC trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,836 shares of the medical research company’s stock after selling 61 shares during the period. LVW Advisors LLC’s holdings in Charles River Laboratories International were worth $768,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. VisionPoint Advisory Group LLC increased its holdings in shares of Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 74 shares during the last quarter. Brown Brothers Harriman & Co. grew its stake in Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after buying an additional 95 shares during the last quarter. Sunbelt Securities Inc. grew its stake in Charles River Laboratories International by 1,072.7% during the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock worth $70,000 after buying an additional 236 shares during the last quarter. GAMMA Investing LLC bought a new position in Charles River Laboratories International during the 4th quarter worth $62,000. Finally, Bruce G. Allen Investments LLC bought a new position in Charles River Laboratories International during the 4th quarter worth $70,000. 98.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on CRL. TD Cowen lowered their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research note on Monday, May 13th. Mizuho assumed coverage on Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 price objective for the company. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a research note on Friday. The Goldman Sachs Group assumed coverage on Charles River Laboratories International in a research note on Thursday, June 6th. They issued a “buy” rating and a $290.00 price target for the company. Finally, StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Hold” and an average price target of $254.50.

Charles River Laboratories International Trading Down 1.7 %

Shares of Charles River Laboratories International stock opened at $203.08 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. The firm has a market cap of $10.46 billion, a price-to-earnings ratio of 23.89, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40. The business has a fifty day simple moving average of $219.57 and a 200-day simple moving average of $232.55. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11 EPS for the current fiscal year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).